These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 5152939)

  • 21. Post-kala-azar dermal leishmaniasis with visceral leishmaniasis, or a rare presentation of visceral leishmaniasis with extensive skin manifestations.
    Ramesh V
    Int J Dermatol; 2007 Dec; 46(12):1326. PubMed ID: 18173544
    [No Abstract]   [Full Text] [Related]  

  • 22. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
    J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
    Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
    Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [South American leishmaniasis in medical practice. Therapeutic problems].
    Heimgartner E; Krebs A
    Schweiz Rundsch Med Prax; 1985 Jul; 74(29):779-83. PubMed ID: 3898301
    [No Abstract]   [Full Text] [Related]  

  • 25. [Mucocutaneous leishmaniasis in otorhinolaryngology].
    Patuano E; Carrat X; Drouet Y; Barnabé D; Vincey P; Berthelot B
    Ann Otolaryngol Chir Cervicofac; 1993; 110(7):415-9. PubMed ID: 8085723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A case report of visceral leishmaniasis in the Tharaka District, Kenya.
    Pelizzi M; Verna M; Vanelli M
    Acta Biomed; 2006 Aug; 77(2):103-5. PubMed ID: 17172190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cutaneous and muucocutaneous leishmaniasis. New findings on the subject].
    Sangüeza P; Cardenas F
    Med Cutan Ibero Lat Am; 1981; 9(1):25-34. PubMed ID: 7022056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Post-kala-azar dermal leishmaniasis with visceral leishmaniasis: a rare presentation.
    Rijal A; Agrawal S; Agarwalla A; Agrawal A; Rijal S
    Int J Dermatol; 2005 Jun; 44(6):494-6. PubMed ID: 15941439
    [No Abstract]   [Full Text] [Related]  

  • 29. [Is kala-azar a diagnostic criterion for acquired immunodeficiency syndrome?].
    Yebra M; Segovia J; Montalbán C; Vargas JA
    Med Clin (Barc); 1989 Nov; 93(16):639. PubMed ID: 2615542
    [No Abstract]   [Full Text] [Related]  

  • 30. [Visceral leishmaniasis with initial skin manifestation of oriental button type followed by skin manifestations of nonindurated lilac scleroatropic and hypodermitis type].
    Saint-André P; Le Vourch C; Labegorre J; Pineau J; André LJ
    Bull Soc Fr Dermatol Syphiligr; 1971; 78(5):538-40. PubMed ID: 5170398
    [No Abstract]   [Full Text] [Related]  

  • 31. [Visceral leishmaniasis and AIDS. Report of 2 cases with cutaneous dissemination].
    Belda Mira A; Díaz Sánchez F; Martínez García B; Gonzalvo Bellver E; Antón Crespo V; Redón Mas J
    An Med Interna; 1994 Aug; 11(8):398-400. PubMed ID: 7772689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Post-kala-azar dermal leishmaniasis or diffuse cutaneous leishmaniasis].
    Cavelier B; Bertail MA; Chemaly P; Bonvalet D; Civatte J
    Ann Dermatol Venereol; 1984; 111(6-7):579-86. PubMed ID: 6497254
    [No Abstract]   [Full Text] [Related]  

  • 33. Macroglossia as a manifestation of post-kala-azar dermal leishmaniasis: a case report.
    Nikzad A; Nobari H; Firooz A; Dowlati Y
    Int J Dermatol; 2005 Feb; 44(2):129-31. PubMed ID: 15689211
    [No Abstract]   [Full Text] [Related]  

  • 34. [Fever, hepatosplenomegaly and hypergammaglobulinemia with leuko- and thrombopenia in kala-azar in a child].
    Peltola H; Rapola J; Jokipii L
    Duodecim; 1980; 96(17):1145-52. PubMed ID: 7249951
    [No Abstract]   [Full Text] [Related]  

  • 35. Oral miltefosine in the treatment of post-kala-azar dermal leishmaniasis.
    Ramesh V; Ansari NA; Jain RK; Salotra P
    Clin Exp Dermatol; 2008 Jan; 33(1):103-5. PubMed ID: 17979988
    [No Abstract]   [Full Text] [Related]  

  • 36. Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome.
    Antinori S; Longhi E; Bestetti G; Piolini R; Acquaviva V; Foschi A; Trovati S; Parravicini C; Corbellino M; Meroni L
    Br J Dermatol; 2007 Nov; 157(5):1032-6. PubMed ID: 17854365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Mucocutaneous Leishmaniasis: an imported illness with ENT repercussions].
    González M; Benito F; García L; Iglesias A
    Acta Otorrinolaringol Esp; 2009; 60(4):298-300. PubMed ID: 19814979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidemiology of visceral leishmaniasis in India.
    Bora D
    Natl Med J India; 1999; 12(2):62-8. PubMed ID: 10416321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of post-kala-azar dermal leishmaniasis.
    Ramesh V
    Int J Dermatol; 1994 Mar; 33(3):153-6. PubMed ID: 8169009
    [No Abstract]   [Full Text] [Related]  

  • 40. [Extermination of kala-azar and cutaneous leishmaniasis on the Dalmatian Islands].
    TARTAGLIA P
    Z Tropenmed Parasitol; 1962 Dec; 13():450-9. PubMed ID: 13993378
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.